title: Post-therapeutic surveillance schedule for oral cancer: is there agreement?
abstract: BACKGROUND
  Patients with oral cavity squamous cell carcinoma represent a diverse group, and the treatment these patients undergo also varies widely. Some patients undergo local excision alone while others require extensive surgery, often with adjuvant chemoradiotherapy. The post-therapeutic surveillance schedule for these patients tends to be a "one size fits all" formula for all head and neck squamous cell carcinoma patients, which has often been dictated by institutional doctrine or a senior surgeon's dogma. The post-therapeutic needs and risks of a T1 oral cancer patient treated with surgery alone differ from those of a patient with advanced laryngeal carcinoma, and the follow-up regimen should be tailored to the specific patient's risk of loco-regional recurrence, distant metastasis, and other related medical issues.
  A total of 65 papers were identified, 18 of which either focused on follow-up strategy for oral cavity squamous cell carcinoma or their tabular data allowed these cases to be extracted. Internationally recognized cancer entities were also queried.
  
  
  CONCLUSIONS
  No international consensus was achieved about the follow-up strategies. The value of post-therapeutic surveillance schedule following oral cancer treatment is generally not in dispute, although patient-initiated symptom-driven visits can be effective in identifying tumor recurrence for oral cancer patients. The range of appointment interval schemes tends to identify a progressive escalation of visit intervals such that there are more visits in the first year than in the second, and fewer yet during the third. Patients may fail to comply with their clinic visit structure. Most references agree that follow-up beyond the third year is unnecessary and may waste medical resources as well as the time of both patient and surgeon. There is no agreement as to the need for or interval of imaging studies.
authors.affiliation: Head and Neck Surgical Associates, 1849 NW Kearney, Suite #300, Portland, OR 97209, USA.
authors.forename: Guicai
authors.initials: G
authors.lastname: Liu
authors.forename: Eric J
authors.initials: EJ
authors.lastname: Dierks
authors.forename: R Bryan
authors.initials: RB
authors.lastname: Bell
authors.forename: Tuan G
authors.initials: TG
authors.lastname: Bui
authors.forename: Bryce E
authors.initials: BE
authors.lastname: Potter
mesh_terms: D001071:Appointments and Schedules; D002294:Carcinoma, Squamous Cell / Q000556:secondary / Q000601:surgery / Q000628:therapy*; D059186:Chemoradiotherapy, Adjuvant; D005500:Follow-Up Studies; D006801:Humans; D009062:Mouth Neoplasms / Q000601:surgery / Q000628:therapy*; D020380:Needs Assessment; D020360:Neoadjuvant Therapy; D009364:Neoplasm Recurrence, Local / Q000473:pathology; D018570:Risk Assessment; D013997:Time Factors